By Nancy Lapid (Reuters) -In patients with melanoma or non-small cell lung cancer, consuming high levels of the artificial ...

The research team led by Senior Researchers Yoonhee Lee from the Division of Biomedical Technology and Gyogwon Koo from the ...

Medically reviewed by Marla Anderson, MD About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Topline data were announced from a phase 3 trial evaluating tarlatamab-dlle (Imdelltra ®) for the treatment of small cell lung cancer (SCLC) in patients who progressed on or after a single line ...

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, ...

Small-cell lung cancer is an aggressive cancer with a 5-year survival below 5% among patients with extensive-stage disease. 1 Although most patients’ tumors respond to frontline platinum-based ...

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

Key Takeaways Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8 ...